New drug duo aims to tackle untreated lymphoma

NCT ID NCT06350318

Recruiting now Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 study is testing a combination of two drugs—rituximab and zanubrutinib—in people with untreated follicular lymphoma or marginal zone lymphoma, both slow-growing B-cell cancers. The goal is to see how well the combo shrinks tumors and how safe it is. About 43 participants will receive both medications, and researchers will track response rates and side effects over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rituximab and zanubrutinib
What this could lead to: If successful, this combination could offer a more effective first treatment for certain slow-growing lymphomas, potentially improving response rates and delaying disease progression.
What could go wrong: This is a small, early-phase trial (43 people) without a comparison group, so results may not prove superiority over standard care. Side effects from the drugs are possible, including infections and bleeding risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm follicular lymphoma Lymphoma, B-Cell, Marginal Zone marginal zone lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B CELL LYMPHOMA FOLLICULAR LYMPHOMA MARGINAL ZONE LYMPHOMA

Contacts and locations

Locations

Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.